Previous 10 | Next 10 |
MIAMI, Feb. 03, 2022 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces that Vifor Fresenius Medical Care Renal Pharma (VFMCRP) has initiated the commercial launch of RAYALDEE ® (extended release calcifediol) in Germany, the first launch of RAYALDEE outside the U.S. ...
The U.S. Food and Drug Administration (FDA) recently refused to approve Pfizer 's (NYSE: PFE) and Opko Health 's (NASDAQ: OPK) growth hormone therapy, somatrogon. In this Motley Fool Live video, recorded on Jan. 26 , Motley Fool contributors Keith Speights and Brian ...
Shares of Opko Health (NASDAQ: OPK) were crashing 32.3% lower this week as of the market close on Thursday, based on data from S&P Global Market Intelligence . The steep decline came after Opko and its partner, Pfizer (NYSE: PFE) , announced after the market clo...
A rough day for the broad market is a downright terrible one for Opko Health (NASDAQ: OPK) . Shares of the drug and diagnostics outfit were down by 23% as of 1:22 p.m. ET on Monday following Friday's post-close announcement that a growth-hormone deficiency treatment co-developed wit...
Pfizer Inc. (NYSE: PFE) and OPKO Health, Inc. (NASDAQ: OPK) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recom...
TOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA ® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health,...
Trading Penny Stocks Today? Here’s What You Need to Know With another day of trading penny stocks and blue chips here and in full effect, there is a lot for investors to keep track of. While volatility remains extremely high right now, having a consistent understanding of the lat...
Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and forme...
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 40 th Annual J.P. Morgan Healthcare Conference being held virtually January 10-13, 2022. Management will be hosting one-on-one meetings with investors and will be participating in a virt...
3 Penny Stocks to Add to Your Watchlist Right Now With 2021 ending just as quickly as it started, penny stocks continue to show potential. Although the last few weeks have been quite up and down as a result of the Omicron variant, in the past day or two, we’ve seen renewed bullis...
News, Short Squeeze, Breakout and More Instantly...
MIAMI, July 18, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that its Board of Directors has authorized the repurchase of up to $100 million of shares of the Company's common stock. Under the repurchase program, OPKO may repurchase shares of its common ...
MIAMI, July 17, 2024 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces it has entered into a $250 million non-dilutive note purchase agreement with HealthCare Royalty (HCRx) secured by OPKO’s profit share payments from Pfizer received pursuant to its license agreement relat...
NextPlat Expands E-Commerce Program in China to Include Broad Retail Distribution and Adds Digital/Social Media Marketing Capabilities with New Marketing Partner PR Newswire New Marketing Partner to Support the Expanded Sales of OPKO-Branded Products Throughout China on Additi...